<DOC>
	<DOCNO>NCT02232490</DOCNO>
	<brief_summary>Phase III , randomize , placebo-controlled , double-blinded trial aim seek therapeutic benefit hepcortespenlisimut-L ( Hepko-V5 ) subject advanced hepatocellular carcinoma .</brief_summary>
	<brief_title>Liver Cancer Immunotherapy : Placebo-controlled Clinical Trial Hepcortespenlisimut-L</brief_title>
	<detailed_description>Phase III , randomize , placebo-controlled , double-blinded trial aim seek therapeutic benefit hepcortespenlisimut-L ( Hepko-V5 ) subject advanced hepatocellular carcinoma . The result compare placebo . The trial duration 3 month consist one stage baseline laboratory evaluation include AFP level follow-up monthly interval . In addition pre-entry abdominal CT scan end-study CT scan preform . The clinical evaluation quantify accord special performance questionnaire .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Subjects least 18 year old willing capable providing inform consent . Both men nonpregnant woman include . HCC diagnosis document prior Study Entry either cytology/histology , CT scan , AFP serum test high equal 30 IU/ml . All subject reproductive potential advise utilize effective contraception throughout course study . Health score status baseline . Agreement participate study give least 3 sample blood lab test . Readily available home address patient find . Subjects might already take V5 prior trial baseline data . Those met inclusion criterion retrospectively enrol . Pregnant breastfeed woman exclude . Subjects take immunomodulatory therapy within 2 month prior Entry : systemic corticosteroid , immune globulin ( IV gamma globulin , IVIG ) , interferon , interleukin , pentoxifylline ( Trental ) , thalidomide , filgrastim ( GCSF ) , sargramostim ( GMCSF ) ; dinitrochlorobenzene ( DNCB ) , thymosin alpha 1 ( thymosin alpha ) , thymopentin , inosiplex ( Isoprinosine ) , polyribonucleoside ( Ampligen ) , ditiocarb sodium ( Imuthiol ) , locally available immune modulators , therapeutic preventive HCC vaccine . Subjects require concurrent participation another experimental research treatment study , receive experimental agent within four week prior Study Entry . Evidence active acute cardiac disease , epilepsy , lifethreatening disease unrelated HCC . Medical condition active alcohol substance abuse , psychological issue opinion local investigator would interfere adherence requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AFP</keyword>
	<keyword>alpha-fetoprotein</keyword>
	<keyword>cancer vaccine</keyword>
	<keyword>cirrhosis</keyword>
	<keyword>hepatitis</keyword>
	<keyword>HCC</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>liver tumor</keyword>
	<keyword>Cholangiocarcinoma</keyword>
</DOC>